Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Open 3.5
Day low 1.95
Close 2.6
They've analysed the first 94 patients with confirmed Covid across the trial population of 45K. Of those infected, 90% did not receive the vaccine. The next analysis occurs after about 160 patients have confirmed Covid.
There is still a LONG way to go!
Although the vaccine news is great, the market reaction has been totally overblown.
This is very preliminary data looking at the first 94 infections in a trial population of 45k. These interim analyses are performed after predetermined numbers of infections. The next is at 160 infections.
Over the next few days, the penny will drop and everybody will realise nothing has changed. Social distancing, masks, and testing will be here for a long time to come.
If P2F is so good, why did BRH sell it for under £3m, and why are they dumping their shares? Doesn’t make sense if this mask is going to be a mega-product.
These masks will definitely sell, but not at the volumes that are being touted on here.
I’m not convinced that the NHS will buy them. Too expensive as each user needs 3-4 per day. Masks have to be replaced between sessions or when a user eats/drinks (ie masks can’t be taken off the face and put on a desk and then reused). So whilst 7 hours is nice, in the real world of use it’s irrelevant.
At £1 per mask, you’re dreaming if you think the NHS will buy any of these in volume when the current masks cost 20p or less.
The NHS doesn’t buy ‘best’ when ‘good enough’ is significantly cheaper!
The company is one apple. It has been sliced into smaller pieces but is still only one apple.
The number of slices does not change the value of the apple but that’s not to say the value will not change. This is down to other factors (and has already happened to the share price here).
As someone else said yesterday, if increasing the value of a company only required the issue of more shares then every country would do this.
Whichever way you cut it, there has been a massive dilution. The share price fell when the new shares are accounted for.
This deal is no different to a discounted placing. If it had been structured as a placing of 600m new shares issued at 0.395p raising £2.375m which was then used to purchase P2F, would anyone be surprised that the share price would then fall?? All the details are in the 21 August RNS.
Looks like classic pump and dump.
Lottohopes - thank you for your posts. Very helpful for new investors looking at this stock for the first time this last 7 days.
Some have made big money here. It does look overbought at the moment but who knows. We live in strange times.
Can’t beat a bit of passive aggression, much appreciated.
I don’t think I said that the process highlighted in my message had been put into production.
There is a lag between proof of concept being published in the scientific literature, testing in prototypes, and actual production. Given that P2F is supposedly the next big thing in Covid, I wanted to see the published research behind their mask/technology. I’m sure someone will know where it has been published and will post a link. It’s not on their website.
Not sure if the mask will have to go through any additional approval processes because it’s virucidal. I’m not an MHRA expert.
Clearly the value is in the patent rather than production.
Thanks.
Slightly bemused by all the excitement over these disposable masks but clearly some have done very well by getting in early.
There are several competing processes in development to produce virucidal masks. Here’s one that has published some data: https://www.sciencedirect.com/science/article/pii/S2666539520300067
I’m sure there’s plenty space in the market but not sure RMS will fly in the way some think.
GLA
Hopefully the Mologic antigen LFT test and/or Avacta LFT test get MHRA approval soon before some other company gets first mover advantage.
At present all patients admitted to hospital, regardless of symptoms, get an NP which is sent for PCR.
Going forward, patients with flu-like symptoms may get Winterplex instead to differentiate flu and Covid. The flu cases may be eligible for Tamiflu.
LFT or another technology might replace PCR based tests in hospitals. I do hope Novacyt’s Microgen division are working on something in this area: https://microgenbioproducts.com/pathflow-2/
"Why didnt Colin RNS first thing this morning?"
As we have seen before, ODX have no control over Abingdon who, as a private company, are not obliged to release an RNS at 7am or other time.
Agree @maxdba.
I have colleagues in the healthworkers arm of the vaccine trial who need regular NP swabs and blood test for antibodies to monitor response.
If the vaccine is shown to work, routine testing won’t be needed. If it’s only partial response then maybe it will.
The market for this test is huge, but I don’t see it necessarily being used routinely in the vaccine program.
You’re correct that antibody testing is used for HepB. As a healthcare worker I was tested 10 years after my first injection and given a booster. However there was no testing after the initial two jabs.
Looking at the other mass testing programs - Flu, MMR, HPV, meningitis - none have antibody testing.
“ antibody test will be needed before administering vaccine and after as well to check if it has worked”
Antibody testing will certainly be required in the Phase 3 trials and possibly in the early part of the roll out. But in the routine vaccination program? Unlikely. Antibodies are not checked for any other vaccine.
Thanks @Mikey-P. Three LFT tests were in the first phase of testing none of which are British. Let’s hope next phase has an ODX test (either Mologic or Avacta).